Recruiting
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
NCT07466316· Phase 3· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Recruiting
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
NCT06465199· Phase 1/2· Milton S. Hershey Medical Center· Source
Contact: Nicole Harvey
Recruiting
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
NCT06900595· Phase 2· National Cancer Institute (NCI)· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945· Phase 3· Boehringer Ingelheim· Source
Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662· Phase 2· National Cancer Institute (NCI)· Source
Contact: Keith J. August (principal investigator)
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157· Phase 2· National Cancer Institute (NCI)· Source
Contact: Keith J. August (principal investigator)
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· Phase 3· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Recruiting
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
NCT06647953· Phase 3· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Recruiting
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
NCT06541262· Phase 1/2· Milton S. Hershey Medical Center· Source
Contact: Nicole Harvey
Recruiting
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817· Phase 2· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Recruiting
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
NCT05711667· Phase 3· Children's Oncology Group· Source
Contact: Lauren C. Wilson (principal investigator)
Recruiting
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097· Phase 2· National Cancer Institute (NCI)· Source
Contact: Keith J. August (principal investigator)
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· Phase 3· National Cancer Institute (NCI)· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT05761171· Phase 2· Children's Oncology Group· Source
Recruiting
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· Phase 3· Children's Oncology Group· Source
Active, not recruiting
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
NCT04203316· Phase 2· Children's Oncology Group· Source
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· Phase 3· National Cancer Institute (NCI)· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
NCT05457556· Phase 3· Children's Oncology Group· Source
Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT05382338· Phase 3· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
NCT05286801· Phase 1/2· National Cancer Institute (NCI)· Source
Recruiting
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585· Phase 3· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
NCT05099003· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
NCT04939597· Phase 3· Children's Oncology Group· Source
Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241· Phase 1/2· PedAL BCU, LLC· Source
Contact: Kevin F. Ginn (principal investigator)
Recruiting
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT05235165· Phase 3· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Recruiting
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944· Phase 1/2· Children's Oncology Group· Source
Contact: Kevin F. Ginn (principal investigator)
Active, not recruiting
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
NCT05071209· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
NCT04759586· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132· Phase 3· Children's Oncology Group· Source
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986· Phase 2· Travere Therapeutics, Inc.· Source
Recruiting
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
NCT04684368· Phase 2· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029· Phase 2· Giselle Sholler· Source
Contact: Nicole Harvey
Active, not recruiting
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT04315324· Phase 1/2· SWOG Cancer Research Network· Source
Recruiting
Beat Childhood Cancer Specimen Banking and Data Registry
NCT04715178· Giselle Sholler· Source
Contact: Nicole Harvey
Active, not recruiting
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
NCT04385277· Phase 2· Children's Oncology Group· Source
Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· Phase 2· National Cancer Institute (NCI)· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
NCT04089358· Phase 3· Children's Oncology Group· Source
Recruiting
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318· Phase 2· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04284774· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
NCT04195399· Phase 2· Children's Oncology Group· Source
Active, not recruiting
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843· Phase 2· Giselle Sholler· Source
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562· Phase 3· Children's Oncology Group· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
NCT04258943· Phase 1/2· Children's Oncology Group· Source
Active, not recruiting
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
NCT03919071· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409· Phase 3· National Cancer Institute (NCI)· Source
Contact: Keith J. August (principal investigator)
Active, not recruiting
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
NCT03871257· Phase 3· National Cancer Institute (NCI)· Source
Showing 50 of 87.